1-deoxynojirimycin has been researched along with eliglustat tartrate in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 3 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Etou, Y | 1 |
| Adera, M; Barlow, C; Barth, J; Bichet, DG; Boudes, P; Eyskens, F; Flanagan, JJ; Goker-Alpan, O; Holida, M; Johnson, FK; Khanna, R; Lockhart, DJ; Nicholls, K; Shankar, S; Sitaraman, S; Thomas, M; Valenzano, KJ; Warnock, DG; Wustman, BA | 1 |
| Ohashi, T | 1 |
| Mignani, R | 1 |
| Capuano, I; Cocozza, S; Feriozzi, S; Ferreri, L; Imbriaco, M; Pisani, A; Riccio, E; Santoro, C; Zanfardino, M | 1 |
| Azevedo, O; Cunha, D; Gago, MF; Miltenberger-Miltenyi, G; Sousa, N | 1 |
| Das, AM; Dungan, L; Garcia, A; Hamler, R; Johnson, FK; Khanna, R; Lun, Y; Martin, L; Perry, A; Schiffmann, R; Schmith, V; Shen, JS; Tsai, PC; Wu, YS | 1 |
3 review(s) available for 1-deoxynojirimycin and eliglustat tartrate
| Article | Year |
|---|---|
[Recent therapeutics for Fabry disease].
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Cell- and Tissue-Based Therapy; Fabry Disease; Genetic Therapy; Glucosamine; Humans; Isoenzymes; Mass Screening; Trihexosylceramides | 2009 |
[Current status and future prospect of enzyme replacement therapy for Fabry disease].
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Animals; Chromosomes, Human, X; Drug Approval; Enzyme Replacement Therapy; Fabry Disease; Female; Globosides; Humans; Isoenzymes; Male; Mice; Molecular Chaperones; Mutation; Randomized Controlled Trials as Topic; Recombinant Proteins; Treatment Outcome | 2019 |
Fabry Disease Therapy: State-of-the-Art and Current Challenges.
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Enzyme Replacement Therapy; Fabry Disease; Humans; Isoenzymes; Recombinant Proteins | 2020 |
1 trial(s) available for 1-deoxynojirimycin and eliglustat tartrate
| Article | Year |
|---|---|
Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
Topics: 1-Deoxynojirimycin; Administration, Oral; Adult; alpha-Galactosidase; Area Under Curve; Demography; Fabry Disease; Humans; Infusion Pumps; Isoenzymes; Male; Middle Aged; Recombinant Proteins; Skin | 2015 |
3 other study(ies) available for 1-deoxynojirimycin and eliglustat tartrate
| Article | Year |
|---|---|
[The Fabry nephropathy: new insight in diagnosis, monitoring and treatment].
Topics: 1-Deoxynojirimycin; alpha-Galactosidase; Disease Progression; Enzyme Replacement Therapy; Fabry Disease; Female; Glomerulosclerosis, Focal Segmental; Glycolipids; Heterozygote; Humans; Isoenzymes; Kidney Diseases; Male; Oxidative Stress; Podocytes; Recombinant Proteins; Sex Factors; Sphingolipids; Trihexosylceramides | 2019 |
Switch from enzyme replacement therapy to oral chaperone migalastat for treating fabry disease: real-life data.
Topics: 1-Deoxynojirimycin; Administration, Oral; Adolescent; Adult; Aged; alpha-Galactosidase; Drug Administration Schedule; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Enzyme Replacement Therapy; Fabry Disease; Humans; Isoenzymes; Male; Middle Aged; Recombinant Proteins | 2020 |
Migalastat Tissue Distribution: Extrapolation From Mice to Humans Using Pharmacokinetic Modeling and Comparison With Agalsidase Beta Tissue Distribution in Mice.
Topics: 1-Deoxynojirimycin; Adult; alpha-Galactosidase; Animals; Female; Humans; Isoenzymes; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Transgenic; Middle Aged; Models, Biological; Species Specificity; Tissue Distribution; Young Adult | 2021 |